Relay Therapeutics target raised to $31, Goldman cites clinical pipeline progress

Goldman Sachs analyst Salveen Richter increased the price target for Relay Therapeutics to $31. The previous target was $22.

Richter also reiterated a Buy rating on the company's shares. The upgrade reflects a positive outlook on the firm's clinical pipeline and developmental progress.